Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 7Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Recurrence 1Patient Preference 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Brain Neoplasms 1

Interventions

pembrolizumab 9avelumab 9Nivolumab 8atezolizumab 4Specimen Handling 4durvalumab 3cemiplimab 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Etoposide 3Cyclophosphamide 3Biopsy 3ALT-803 3talimogene laherparepvec 2fludarabine phosphate 2fludarabine 2domatinostat 2Radiosurgery 2Ipilimumab 2Cisplatin 2Carboplatin 2relatlimab 1oblimersen 1lutetium Lu 177 dotatate 1lenvatinib 1lanreotide 1daromun 1cabozantinib 1antineoplaston AS 2-1 1antineoplaston A10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Merkel Cell × Opdualag × Clear all
NCT06151236 2026-02-17

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Melanoma Institute Australia

Phase 2 Recruiting
20 enrolled
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡